New Age Alpha Advisors LLC Takes Position in Option Care Health, Inc. (NASDAQ:OPCH)

New Age Alpha Advisors LLC bought a new position in shares of Option Care Health, Inc. (NASDAQ:OPCH) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 6,389 shares of the company’s stock, valued at approximately $148,000.

A number of other hedge funds have also added to or reduced their stakes in OPCH. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Option Care Health by 84.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 70,119 shares of the company’s stock worth $2,195,000 after buying an additional 32,142 shares during the last quarter. Martingale Asset Management L P acquired a new position in Option Care Health during the third quarter valued at approximately $287,000. Atom Investors LP bought a new position in Option Care Health in the third quarter valued at approximately $485,000. HighTower Advisors LLC increased its position in shares of Option Care Health by 10.0% during the 3rd quarter. HighTower Advisors LLC now owns 401,061 shares of the company’s stock worth $12,514,000 after purchasing an additional 36,308 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Option Care Health by 4.1% during the 3rd quarter. Janus Henderson Group PLC now owns 214,081 shares of the company’s stock worth $6,699,000 after purchasing an additional 8,467 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.

Option Care Health Price Performance

Shares of NASDAQ OPCH opened at $34.79 on Thursday. The firm has a market cap of $5.71 billion, a P/E ratio of 29.24, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33. The business’s 50 day moving average is $32.80 and its 200-day moving average is $28.47. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on OPCH shares. Jefferies Financial Group raised shares of Option Care Health from a “hold” rating to a “buy” rating and raised their target price for the company from $26.00 to $35.00 in a research note on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and set a $30.00 price objective (down from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. UBS Group assumed coverage on shares of Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Barrington Research boosted their price target on Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. Finally, Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and raised their price objective for the company from $26.00 to $33.00 in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Option Care Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Insiders Place Their Bets

In other news, insider Michael Bavaro sold 30,996 shares of the business’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the sale, the insider now owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. The trade was a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.64% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.